Titre
Treatment of sepsis: past and future avenues
Type
synthèse (review)
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
Baumgartner, J. D.
Auteure/Auteur
Calandra, T.
Auteure/Auteur
Liens vers les personnes
Liens vers les unités
ISSN
0012-6667
Statut éditorial
Publié
Date de publication
1999-02
Volume
57
Numéro
2
Première page
127
Dernière page/numéro d’article
32
Peer-reviewed
Oui
Notes
Journal Article
Research Support, Non-U.S. Gov't
Review --- Old month value: Feb
Research Support, Non-U.S. Gov't
Review --- Old month value: Feb
Résumé
In recent years, the concept has emerged that the host's inflammatory response contributes substantially to the development of septic shock and organ failure. Experimental observations prompted large scale randomised clinical trials with a variety of agents such as glucocorticoids, ibuprofen, antiendotoxin monoclonal antibodies, antagonists of platelet-activating factor, of bradykinin or of interleukin-1 receptor, and monoclonal anti-tumour necrosis factor (TNF) antibodies or soluble dimeric TNF receptor fusion proteins. All these major studies of immunomodulators in sepsis have yielded disappointing results despite showing promise during preliminary clinical studies. However, these recent failures do not mean that septic shock will forever remain an insurmountable medical challenge. Many lessons have been learned from these studies. and certain mistakes in their study design will be avoided in the future. Our understanding of the pathophysiology of sepsis and septic shock is increasing markedly; potential new treatment strategies are available and could be explored to improve the outcome of patients with sepsis.
Sujets
PID Serval
serval:BIB_E2CF03AE23AB
PMID
Date de création
2008-01-19T17:12:29.265Z
Date de création dans IRIS
2025-05-21T03:03:56Z